Save your place

Sign in to WhoBought

Please try again later.

Bicara Therapeutics Inc. Common Stock (BCAX) institutional ownership

Latest close $27.96 Jul 22, 2026
Market cap$574M 52-week range SectorHealthcare
Funds holding · Q1 2026
142
reported BCAX position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
81 buyers · 61 sellers

Bicara Therapeutics Inc. Common Stock (BCAX) price and institutional activity

Dates

Q1 2026

$0 bought by 81 investors
T. Rowe Price Investment Management, Inc.Vestal Point Capital, LP +79 more
$0 sold by 61 investors
FMR LLCMillennium Management LLC +59 more
Bought Sold Totals per quarter; hover a bar for the names.

Bicara Therapeutics Inc. Common Stock (BCAX) institutional activity · 142

Investor Type Est. change Change Δ Own Date
T. Rowe Price Investment Management, Inc. · Added
Change +3.4M Date Q1 2026
T. Rowe Price Investment Management, Inc. Added· Q1 2026 +3.4M Q1 2026
Vestal Point Capital, LP · Added
Change +1.9M Date Q1 2026
Vestal Point Capital, LP Added· Q1 2026 +1.9M Q1 2026
Deep Track Capital, LP · Added
Change +1.4M Date Q1 2026
Deep Track Capital, LP Added· Q1 2026 +1.4M Q1 2026
Jones Hill Capital LP · New
Change +1.3M Date Q1 2026
Jones Hill Capital LP New· Q1 2026 +1.3M Q1 2026
FMR LLC · Reduced
Change −1.2M Δ Own −37.2% Date Q1 2026
FMR LLC Reduced· Q1 2026 −1.2M −37.2% Q1 2026
Royalty Pharma Sub-Manager, LLC · Added
Change +1.1M Date Q1 2026
Royalty Pharma Sub-Manager, LLC Added· Q1 2026 +1.1M Q1 2026
Atle Fund Management AB · Added
Change +1.1M Date Q1 2026
Atle Fund Management AB Added· Q1 2026 +1.1M Q1 2026
Citadel Advisors LLC Added· Q1 2026 +887K +114.9% Q1 2026
Janus Henderson Group PLC · Added
Change +693K Date Q1 2026
Janus Henderson Group PLC Added· Q1 2026 +693K Q1 2026
Siren, L.L.C. · Added
Change +586K Date Q1 2026
Siren, L.L.C. Added· Q1 2026 +586K Q1 2026
Orbimed Advisors LLC · Added
Change +458K Date Q1 2026
Orbimed Advisors LLC Added· Q1 2026 +458K Q1 2026
BlackRock · Added
Change +315K Date Q1 2026
BlackRock Added· Q1 2026 +315K Q1 2026
Morgan Stanley · Added
Change +312K Date Q1 2026
Morgan Stanley Added· Q1 2026 +312K Q1 2026
Ra Capital Management, L.P. · Added
Change +300K Date Q1 2026
Ra Capital Management, L.P. Added· Q1 2026 +300K Q1 2026
Millennium Management LLC · Reduced
Change −278K Date Q1 2026
Millennium Management LLC Reduced· Q1 2026 −278K Q1 2026
Data through Q1 2026 · filed Jun 2, 2026
15 of 142

Famous investor activity in Bicara Therapeutics Inc. Common Stock (BCAX)

Bicara Therapeutics Inc. Common Stock (BCAX) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Mazumdar Claire · Director 2 operations −$284K
Price $28.42–$29.68 Qty −10K Owned 362K ΔOwn −2.7% Trade date Jul 10, 2026 Filed date Jul 14, 2026
Mazumdar Claire Director 2 operations $28.42–$29.68 −10K −$284K 362K −2.7% Jul 10, 2026 Jul 14, 2026
Mazumdar Claire · Director 2 operations 0
Price $3.79 Owned 121K Trade date Jul 10, 2026 Filed date Jul 14, 2026
Mazumdar Claire Director 2 operations $3.79 0 121K Jul 10, 2026 Jul 14, 2026
Cohlhepp Ryan · Director Sell −$16K
Price $29.00 Qty −536 Owned 182K ΔOwn −0.3% Trade date Jul 9, 2026 Filed date Jul 10, 2026
Cohlhepp Ryan Director Sell $29.00 −536 −$16K 182K −0.3% Jul 9, 2026 Jul 10, 2026
Cohlhepp Ryan · Director 3 operations −$818K
Price $28.76–$30.35 Qty −28K Owned 182K ΔOwn −13.4% Trade date Jul 8, 2026 Filed date Jul 10, 2026
Cohlhepp Ryan Director 3 operations $28.76–$30.35 −28K −$818K 182K −13.4% Jul 8, 2026 Jul 10, 2026
Cohlhepp Ryan · Director 2 operations 0
Price $3.79 Owned 71K Trade date Jul 8, 2026 Filed date Jul 10, 2026
Cohlhepp Ryan Director 2 operations $3.79 0 71K Jul 8, 2026 Jul 10, 2026
Hyep Ivan · Officer 3 operations −$808K
Price $28.60–$30.31 Qty −28K Owned 130K ΔOwn −17.7% Trade date Jul 8, 2026 Filed date Jul 10, 2026
Hyep Ivan Officer 3 operations $28.60–$30.31 −28K −$808K 130K −17.7% Jul 8, 2026 Jul 10, 2026
Hyep Ivan · Officer 3 operations 0
Price $3.79 Owned 39K Trade date Jul 8, 2026 Filed date Jul 10, 2026
Hyep Ivan Officer 3 operations $3.79 0 39K Jul 8, 2026 Jul 10, 2026
Ra Capital Management, L.P. · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Ra Capital Management, L.P. Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Bowden Christopher · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Bowden Christopher Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Haviland Kate · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Haviland Kate Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Mazumdar-Shaw Kiran · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Mazumdar-Shaw Kiran Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Robertson Scott M. · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Robertson Scott M. Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Powell Michael · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Powell Michael Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Simson Jake · Director Grant (A) 19K
Owned 19K Trade date Jun 9, 2026 Filed date Jun 10, 2026
Simson Jake Director Grant (A) 19K 19K Jun 9, 2026 Jun 10, 2026
Hyep Ivan · CFO Sell −$188K
Price $20.42 Qty −9K Owned 145K Trade date May 21, 2026 Filed date May 26, 2026
Hyep Ivan CFO Sell $20.42 −9K −$188K 145K May 21, 2026 May 26, 2026
15 of 118
15 of 118 Sign in to continue to older insider transactions.

Bicara Therapeutics Inc. Common Stock (BCAX) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Ra Capital Management, L.P. 7.0M
% of shares outstanding 12.8% Filing date Sep 23, 2024
Ra Capital Management, L.P. 7.0M 12.8% Sep 23, 2024
Vestal Point Capital, LP 5.4M
% of shares outstanding 8.3% Filing date May 15, 2026
Vestal Point Capital, LP 5.4M 8.3% May 15, 2026
Deep Track Capital, LP 4.1M
% of shares outstanding 6.2% Filing date May 15, 2026
Deep Track Capital, LP 4.1M 6.2% May 15, 2026
Invus Global Management, LLC 3.0M
% of shares outstanding 5.6% Filing date Sep 26, 2024
Invus Global Management, LLC 3.0M 5.6% Sep 26, 2024
Tpg Gp A, LLC 3.0M
% of shares outstanding 5.5% Filing date Sep 18, 2024
Tpg Gp A, LLC 3.0M 5.5% Sep 18, 2024
Janus Henderson Group PLC 3.3M
% of shares outstanding 5.1% Filing date May 15, 2026
Janus Henderson Group PLC 3.3M 5.1% May 15, 2026
Red Tree Gp, LLC 3.2M
% of shares outstanding 4.8% Filing date May 8, 2026
Red Tree Gp, LLC 3.2M 4.8% May 8, 2026
FMR LLC 2.1M
% of shares outstanding 3.2% Filing date May 6, 2026
FMR LLC 2.1M 3.2% May 6, 2026
8 of 8

Bicara Therapeutics Inc. Common Stock (BCAX) ownership FAQ

Who owns BCAX?

142 reporting institutions disclosed BCAX position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.